Cumberland Posts $77.8M Q3 Net Income on Divestiture Gain; $80.6M Cash
CPIX has more than doubled off its 52-week low of $1.85 on elevated volume (2.0× avg).
Summary
Cumberland's first full quarter as a development-only company produced $77.8 million of net income, almost entirely the gain on the $100 million Apotex divestiture, and left $80.6 million of cash to fund the ifetroban NDA.
Key Events · Earnings and Guidance · CPIX
-
Q3 Net Income of $77.8 Million
For the three months ended September 30, 2026, net income attributable to common shareholders was $77.8 million, or $5.19 per basic share.
-
Profit Is a Divestiture Gain
An $81.1 million gain on disposal of discontinued operations drove the quarter; continuing operations actually lost $1.1 million in Q3 and $7.2 million over nine months.
-
Cash Position of $80.6 Million
Cash and cash equivalents reached $80.6 million at September 30, 2026, up from $11.4 million at December 31, 2025, against $42 million of total liabilities and $73 million of shareholders' equity.
-
Rolling NDA Planned for Ifetroban
Following a pre-NDA meeting with the FDA, Cumberland will submit a rolling NDA for ifetroban in DMD cardiomyopathy, supported by the Phase 2 FIGHT DMD trial's 5.4 percentage point improvement in left ventricular ejection fraction (p=0.002).
Analysis · CPIX · Life Sciences
The headline profit is an accounting event, not an operating one: $81.1 million of the $77.8 million came from the gain on selling the commercial business to Apotex, while continuing operations lost $1.1 million in the quarter. What actually matters is the balance sheet — $80.6 million of cash against $42 million of liabilities gives Cumberland a funded runway to take ifetroban into a rolling NDA for DMD cardiomyopathy without raising money in the near term. The offset is that revenue is now minimal ($206,356 of net revenue plus $1.95 million of transition services), so the entire equity story rests on the ifetroban regulatory path and the FDA's willingness to accept the Phase 2 plus natural-history package.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CPIX was trading at $5.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $79.4M. The 52-week trading range was $1.85 to $9.28. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.